The British government unveiled a £20 billion financial support package for exporters hit by punishing new US tariffs, framing it as essential to provide stability in an increasingly volatile global trade environment. This comes after Washington imposed swingeing 25% duties on British steel, aluminium and automobiles, alongside a blanket 10% levy on most other UK goods – measures that have sent shockwaves through British industry.
While ministers boast that the funding will increase UK Export Finance’s (UKEF) lending capacity to £80 billion – with £10 billion earmarked for immediate relief to hardest-hit sectors – the figures reveal an uncomfortable truth. Last year alone, UK exports to the US totalled £187 billion, meaning this “rescue package” amounts to barely 10% of a single year’s trade volume with America. The tariffs, if sustained, could erase that entire sum within months.
Chancellor Rachel Reeves insisted the world had changed, arguing that unprecedented support was now critical to shore up Britain’s global businesses against mounting trade barriers. She claimed thousands of firms nationwide would benefit, though conspicuously avoided specifying how many jobs might still be lost.
The move exposes Britain’s precarious position as both sides of the Atlantic engage in economic trench warfare. With UK manufacturers already reeling from supply chain disruptions and the lingering Brexit fallout, these tariffs threaten to kneecap strategic industries. The automotive sector, which exported £20 billion worth of vehicles to the US last year, now faces potential annual tariff bills exceeding £5 billion – dwarfing the government’s proposed aid.
Behind the fanfare, Whitehall’s scramble to mitigate the damage appears dangerously reactive. The £20 billion, while headline-grabbing, represents less than 1% of the UK’s annual GDP – hardly the “game-changing intervention” ministers describe. As trade experts point out, no amount of financial sticking plasters can compensate for severed access to Britain’s largest export market. With Washington showing no signs of backing down, this subsidy may prove little more than a temporary painkiller for a terminal diagnosis.
